A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Loncastuximab tesirine (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 05 Jun 2023 Planned End Date changed from 1 Aug 2027 to 1 Feb 2028.
- 05 Jun 2023 Planned primary completion date changed from 1 Aug 2025 to 1 Feb 2026.
- 05 Jun 2023 Status changed from not yet recruiting to recruiting.